HRP20181570T1 - Režim doziranja spoja fgf-18 - Google Patents

Režim doziranja spoja fgf-18

Info

Publication number
HRP20181570T1
HRP20181570T1 HRP20181570TT HRP20181570T HRP20181570T1 HR P20181570 T1 HRP20181570 T1 HR P20181570T1 HR P20181570T T HRP20181570T T HR P20181570TT HR P20181570 T HRP20181570 T HR P20181570T HR P20181570 T1 HRP20181570 T1 HR P20181570T1
Authority
HR
Croatia
Prior art keywords
fgf
compound
dosage mode
dosage
mode
Prior art date
Application number
HRP20181570TT
Other languages
English (en)
Croatian (hr)
Inventor
Christoph H. Ladel
Hans Guehring
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HRP20181570T1 publication Critical patent/HRP20181570T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2006IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20181570TT 2014-02-20 2015-02-20 Režim doziranja spoja fgf-18 HRP20181570T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600 2014-02-20
EP15706006.2A EP3107559B1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen
PCT/EP2015/053624 WO2015124727A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (1)

Publication Number Publication Date
HRP20181570T1 true HRP20181570T1 (hr) 2018-11-30

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20181570TT HRP20181570T1 (hr) 2014-02-20 2015-02-20 Režim doziranja spoja fgf-18
HRP20181572TT HRP20181572T1 (hr) 2014-02-20 2015-02-20 Režim doziranja spoja fgf-18

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20181572TT HRP20181572T1 (hr) 2014-02-20 2015-02-20 Režim doziranja spoja fgf-18

Country Status (25)

Country Link
US (2) US9889179B2 (enExample)
EP (2) EP3107559B1 (enExample)
JP (2) JP6431082B2 (enExample)
KR (2) KR102410986B1 (enExample)
CN (2) CN106456713A (enExample)
AR (2) AR099510A1 (enExample)
AU (2) AU2015220777B2 (enExample)
BR (2) BR112016018685A2 (enExample)
CA (2) CA2938793A1 (enExample)
DK (2) DK3107559T3 (enExample)
ES (2) ES2689071T3 (enExample)
HR (2) HRP20181570T1 (enExample)
HU (1) HUE040350T2 (enExample)
IL (2) IL247084B (enExample)
LT (2) LT3119417T (enExample)
MX (2) MX2016010872A (enExample)
NZ (2) NZ723139A (enExample)
PL (2) PL3119417T3 (enExample)
PT (2) PT3119417T (enExample)
RS (2) RS57709B1 (enExample)
RU (2) RU2700582C2 (enExample)
SG (2) SG11201606502YA (enExample)
SI (2) SI3107559T1 (enExample)
WO (2) WO2015124731A1 (enExample)
ZA (2) ZA201605547B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3119417T (pt) 2014-02-20 2018-10-31 Merck Patent Gmbh Regime posológico de composto de fgf-18
MX368946B (es) 2014-02-20 2019-10-22 Merck Patent Gmbh Implante que contiene factor de crecimiento de fibroblastos 18.
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
RU2743075C2 (ru) 2016-02-22 2021-02-15 Новартис Аг Способы применения агонистов fxr
EP3688468B1 (en) 2017-09-29 2022-03-16 Merck Patent GmbH Inflammatory biomarkers for predicting responsiveness to fgf-18 compound
RS63293B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Metabolički biomarkeri za predviđanje reakcije na jedinjenje fgf-18
HUE067058T2 (hu) 2018-09-10 2024-09-28 Merck Patent Gmbh Oszteoartritisz kezelésére szolgáló dúsítási stratégiákban alkalmazható markerek
AU2020218844A1 (en) * 2019-02-08 2021-08-19 Merck Patent Gmbh Treatment of patients at risk of rapid progression of osteoarthritis
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4754823B2 (ja) * 2002-10-07 2011-08-24 ザイモジェネティクス, インコーポレイテッド Fgf18の投与方法
EP2327413A1 (en) * 2004-07-06 2011-06-01 ZymoGenetics, Inc. Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
PL2054050T3 (pl) * 2006-08-25 2013-01-31 Ares Trading Sa Leczenie zaburzeń chrząstki z zastosowaniem FGF-18
BRPI0715728A8 (pt) * 2006-08-25 2018-04-03 Ares Trading Sa tratamento de distúrbios cartilaginosos
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
EP2688890B1 (en) * 2011-03-22 2017-08-30 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
PT3119417T (pt) 2014-02-20 2018-10-31 Merck Patent Gmbh Regime posológico de composto de fgf-18
MX368946B (es) 2014-02-20 2019-10-22 Merck Patent Gmbh Implante que contiene factor de crecimiento de fibroblastos 18.
MX2016010873A (es) 2014-02-20 2016-11-17 Merck Patent Gmbh Factor de crecimiento de fibroblastos 18 en los procedimientos para el trasplante de injertos y para ingenieria de tejidos.

Also Published As

Publication number Publication date
LT3107559T (lt) 2018-10-25
ZA201605547B (en) 2019-09-25
CA2938793A1 (en) 2015-08-27
IL247083A0 (en) 2016-09-29
AU2015220773A1 (en) 2016-09-01
CN106232622A (zh) 2016-12-14
RS57709B1 (sr) 2018-12-31
KR102410988B1 (ko) 2022-06-17
HRP20181572T1 (hr) 2018-11-30
AR099510A1 (es) 2016-07-27
ES2688551T3 (es) 2018-11-05
SI3119417T1 (sl) 2018-11-30
CA2938791A1 (en) 2015-08-27
AU2015220777B2 (en) 2020-10-22
US9724388B2 (en) 2017-08-08
RU2016137292A3 (enExample) 2018-09-17
US9889179B2 (en) 2018-02-13
SG11201606505UA (en) 2016-09-29
PL3107559T3 (pl) 2019-01-31
PL3119417T3 (pl) 2019-01-31
EP3119417A1 (en) 2017-01-25
US20170056474A1 (en) 2017-03-02
RU2016137289A3 (enExample) 2018-10-19
MX2016010871A (es) 2016-11-17
WO2015124727A1 (en) 2015-08-27
HUE040350T2 (hu) 2019-03-28
JP2017507142A (ja) 2017-03-16
MX2016010872A (es) 2016-11-17
EP3107559B1 (en) 2018-07-11
KR102410986B1 (ko) 2022-06-17
KR20160116001A (ko) 2016-10-06
CN106456713A (zh) 2017-02-22
RU2016137289A (ru) 2018-03-21
NZ723139A (en) 2022-12-23
RU2016137292A (ru) 2018-03-21
BR112016018696A2 (pt) 2017-10-17
AU2015220773B2 (en) 2020-10-08
RU2700582C2 (ru) 2019-09-18
LT3119417T (lt) 2018-10-25
IL247084B (en) 2019-09-26
AU2015220777A1 (en) 2016-09-01
SG11201606502YA (en) 2016-09-29
IL247083B (en) 2019-09-26
WO2015124731A1 (en) 2015-08-27
RU2691946C2 (ru) 2019-06-19
JP6431082B2 (ja) 2018-11-28
ZA201605548B (en) 2018-12-19
KR20160116000A (ko) 2016-10-06
JP2017512194A (ja) 2017-05-18
DK3119417T3 (en) 2018-10-22
JP6431083B2 (ja) 2018-11-28
PT3119417T (pt) 2018-10-31
SI3107559T1 (sl) 2018-11-30
IL247084A0 (en) 2016-09-29
EP3119417B1 (en) 2018-07-11
BR112016018685A2 (pt) 2017-10-17
PT3107559T (pt) 2018-10-31
EP3107559A1 (en) 2016-12-28
RS57853B1 (sr) 2018-12-31
NZ723148A (en) 2022-08-26
US20170072017A1 (en) 2017-03-16
ES2689071T3 (es) 2018-11-08
AR099558A1 (es) 2016-08-03
DK3107559T3 (en) 2018-10-15

Similar Documents

Publication Publication Date Title
IL281863A (en) Pharmaceutical compositions comprising meloxicam
HUE047477T2 (hu) Palbociclib szilárd dózisformái
HUE050732T2 (hu) Új vegyületek
LT3134402T (lt) 4-amino-imidazochinolino junginiai
HUE059694T2 (hu) Készítmény rák kezelésére
DK3310231T3 (da) Doseringsindretning
PT3298027T (pt) Compostos depsipéptidos antelmínticos
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
HUE059158T2 (hu) Eljárás pridopidin elõállítására
HRP20181570T1 (hr) Režim doziranja spoja fgf-18
DK3363428T3 (da) Perfusionsdoseringsform
DK3283210T3 (da) Fremgangsmåde
BR112016030730A2 (pt) Composto
DK3145488T3 (da) Flydende farmaceutiske forbindelse
LT3212237T (lt) Metotreksato vaistinė forma
LT3362444T (lt) Junginiai
IL250613B (en) Substituted bicyclic compounds
DK3597189T3 (da) Krystallinske forbindelser
IL246509A0 (en) Coordinating multiple components
IL254502B (en) Solid forms of menaquinols
DK3191466T3 (da) Azetidinyloxyphenylpyrrolidinforbindelser
HUE049170T2 (hu) Eljárás szubsztituált cikloszerinek elõállítására
HUE039805T2 (hu) Új szulfonilaminobenzamid vegyületek
DK3347403T3 (da) Polyalkoxyfedtforbindelse
LT3331885T (lt) Junginiai